Sirolimus (rapamycin)
Email me the evidence briefComparisons
ComparisonsSirolimus vs acarbose: comparing the longevity evidenceBoth extend mouse lifespan in the NIA ITP. Only one is FDA-approved for anything. Here's how rapamycin and acarbose actually compare for longevity use.Read guide →ComparisonsSirolimus vs metformin for longevity: what the evidence saysRapamycin extends mouse lifespan up to 26% in NIA-funded trials; metformin's own aging trial (TAME) never got funded. Neither has human longevity data.Read guide →ComparisonsSirolimus vs NAD+: comparing the longevity evidenceSirolimus has decade-long mouse lifespan data from the NIA's ITP; NAD+ boosters mostly have biomarker studies. Neither has a completed human lifespan trial.Read guide →ComparisonsSirolimus vs rapamycin vs everolimus: what's differentSirolimus and rapamycin are the same drug. Everolimus is a cousin. Here's what differs in half-life, dosing, and the human longevity data (none of it complete).Read guide →ComparisonsSirolimus vs senolytics: how the longevity evidence comparesRapamycin has NIA-backed mouse lifespan data; senolytics like dasatinib+quercetin don't. Neither has a completed human lifespan trial. Compare the evidence.Read guide →